Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Barbara Burtness(Yale University), Ezra E.W. Cohen(Moores Cancer Center), Irina A. Vasilevskaya, Jan B. Vermorken(University of Antwerp), Daniel Rauch(University Hospital of Bern), Makoto Tahara(National Cancer Center Hospital East), Ulisses Ribaldo Nicolau(AC Camargo Hospital), Naomi Kiyota(Kobe University Hospital), Petra Holečková(Charles University), Luciano de Souza Viana(Hospital de Câncer de Barretos), Chaitali Nangia(University of California, Irvine Medical Center), José Trigo(Heidelberg University), Amanda Psyrri(National and Kapodistrian University of Athens), Akihiro Homma(Hokkaido University), José Dinis(IPO Porto), И. С. Романов(Russian Cancer Research Center NN Blokhin), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Nirav Asarawala(Shree Krishna Hospital), Jean Bourhis(University of Lausanne), Robert I. Haddad(Georgetown University), Bushi Wang(Boehringer Ingelheim (United States)), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Manuel Chaves-Conde(Hospital Universitario Virgen del Rocío), J.M. del Campo(Vall d'Hebron Hospital Universitari), José Getulio Martins Segalla(Hospital Amaral Carvalho), Caroline Even(Institut Gustave Roussy), Tomoya Yokota(Target (United States)), Neil Gibson(Boehringer Ingelheim (Germany))
Cited by 43
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k